In this context, it is fundamental to specify that not all kinds of intra-tumor neo-vascular endothelium has significant PSMA expression and that some kinds of tumors show weak neo-angiogenesis; this implies that PSMA-targeting radiopharmaceuticals might not be employed in every type of cancer [21]. Here, FOLH1 is linked to cancer.